Want to find out how to procure cost-saving innovations and be reimbursed?
The NHS Innovation Accelerator (NIA) is to host a series of information events in partnership with local Academic Health Science Networks to demonstrate how NHS commissioners and providers can be reimbursed for the procurement of cost-saving, outcomes-based innovations.
The ‘Improving outcomes, cutting costs’ events will specifically showcase the five NIA innovations available to procure via central funding and the new Innovation and Technology Tariff (ITT) from 1 April 2017. NHS England will also be introducing the ITT and providing insight as to how it will work.
Why should I attend?
Attendees will be able to access some of the country’s best evidence-based innovations and be reimbursed by NHS England; learn how these innovations have improved efficiencies, benefitted patients and secured cost savings across other NHS organisations; meet the NIA Fellows who represent these innovations and see first-hand how they work; and find out how to replicate these benefits across your organisation.
These innovations include:
- MyCOPD: An online self-management system for COPD proven to correct 98% of patient inhaler errors without clinical involvement, to reduce acute hospital admissions, improve the quality of patients’ lives and save (for an average CCG – with a COPD population of around 5,000 patients ) £200,000 in the first year alone.
- The Non-Injectable Arterial Connector: This is a Patient safety device which stops medication being accidentally given through the arterial lines used to monitor the blood of patients in ICUs and operating theatres. It improves safety and infection control, while offering regional savings of over £156,500 per year.
- PneuX Prevention System: Patient safety device designed to prevent ventilator-associated pneumonia (VAP), which affects approximately 20,000 patients each year.
- Episcissors-60: This device will help to guide a mediolateral episiotomy, evidenced to minimise the risk of obstetric anal sphincter injury (OASIS), therefore delivering savings through reduced OASIS repair.
- AliveCor’s Kardia: This mobile ECG device is used for the identification and measurement of atrial fibrillation (AF) ,the cause of between 25,000-35,000 strokes in the UK per year.
How to register for ‘Improving outcomes, cutting costs’
Register via the links below to attend one of four events in Birmingham, Leeds, Oxford and London. Places are limited, so attendees are advised to register as soon as possible.
For more information e-mail Rebekah Tailor, NIA Communications and Engagement Manager: email@example.com
Posted on March 27, 2017